Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
Saved in:
| Title: | Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx |
|---|---|
| Authors: | Fulgent Genetics, Inc. |
| Source: | Business Wire (English). 03/17/2026. |
| Abstract: | Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025. [ABSTRACT FROM PUBLISHER] |
|---|
